SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT"), a life sciences company
developing stem cell-related technologies, today announced that it has signed a
definitive debenture purchase and merger agreement with Trillium Therapeutics
Inc. ("Trillium") and its debenture holders, who also comprise the preferred
shareholders. The debenture holders, who intend to vote in favour of the merger
at a meeting of shareholders of Trillium to be held on April 5, 2013, have
converted their preference shares to common shares and now hold greater than the
two-thirds majority of the common shares required to approve the merger. SCT
believes that the merger will be concluded, subject to certain events required
by SCT.


SCT and Trillium previously announced the signing of a Letter of Agreement on
February 4, 2013, and provided the details of the merger. The originally
anticipated closing date of March 31, 2013 has been extended by mutual consent
of SCT and Trillium to accommodate the timing of the Trillium shareholder
meeting. 


SCT also announced that it has met the conditions to exercise the option to
exclusively license the clinical stem cell program from the University Health
Network and MaRS Innovation announced on November 7, 2012, and is proceeding to
finalize the corresponding license agreement.


In other news, the Company has closed its U.S. private placement offering of
units. Gross proceeds from the two financings, including the previously
announced shelf prospectus drawdown on March 15, 2013, now total $3,185,080.
Griffin Securities and Roth Capital Partners served as financial advisors in the
U.S.


This news release shall not constitute an offer to sell nor the solicitation of
an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such
jurisdiction.


About Stem Cell Therapeutics: 

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) develops stem cell-based
therapeutics through partnerships with research institutions and technology
transfer organizations. SCT's objectives include the sourcing and acquisition of
stem cell-related development opportunities, and securing capital for the
advancement of its licensed or acquired products. The Corporation's intended
corporate acquisitions and licensed acquisitions are positioning it principally
in the field of cancer stem cell therapeutic development. SCT is a member of the
Centre for Commercialization of Regenerative Medicine consortium. For more
information, visit: www.stemcellthera.com


Forward Looking Statements

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, but are not limited to, the closing of the offering; SCT's
ability to obtain financing in connection with the proposed transaction with
Trillium; uncertainties as to the timing and closing of the proposed transaction
with Trillium; the satisfaction of the conditions precedent to the completion of
the proposed transaction with Trillium; the satisfaction of the conditions
precedent to the exercise of the option to acquire a license to certain
technologies owned by University Health Network; the exercise of the option to
acquire a license to certain technologies owned by University Health Network;
the execution and delivery of a definitive license agreement with University
Health Network if SCT determines to exercise the University Health Network
option; changing market conditions; the successful and timely completion of
pre-clinical and clinical studies; the establishment of corporate alliances; the
impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting, including in the base shelf prospectus dated March 1, 2011 and any
prospectus supplement. Except as required by applicable securities laws, SCT
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
David Allan
Executive Chairman
+1 647 258 4325
DAllan@StemCellThera.com
www.StemCellThera.com

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024